Product nameAnti-FGFR1 (phospho Y654) antibody
See all FGFR1 primary antibodies
DescriptionRabbit polyclonal to FGFR1 (phospho Y654)
SpecificityBinds human and mouse FGFR1 only when phosphorylated at tyrosine 654 and rat FGFR1 only when phosphorylated at tyrosine 561.
Tested applicationsSuitable for: IHC-P, ICC/IF, WB, ELISAmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to Human FGFR1. Synthetic phosphopeptide (Human) from around the phosphorylation site of tyrosine 654 (DYYPKK)
Database link: P11362
- WB: 293 and HeLa cell lysates treated with EGF, 293 cell extract treated with insulin. IHC-P: Human breast adenocarcinoma. ICC/IF: SKNSH cells. COS7 cells.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg+2 and Ca+2
Concentration information loading...
PurityImmunogen affinity purified
Purification notesAffinity purified from rabbit antiserum by affinity chromatography using epitope specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab59194 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||1/500 - 1/1000. Detects a band of approximately 117 kDa (predicted molecular weight: 92 kDa).|
FunctionReceptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
Tissue specificityDetected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
Involvement in diseaseDefects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsBinding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
Cellular localizationMembrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
- Information by UniProt
- Basic fibroblast growth factor receptor 1 antibody
- bFGF-R-1 antibody
- BFGFR antibody
All lanes : Anti-FGFR1 (phospho Y654) antibody (ab59194) at 1/1000 dilution
Lane 1 : 293 untreated lysates
Lane 2 : 293 treated with 200 ng/mL EGF for 30 minutes
Lane 3 : HeLa untreated lysates
Lane 4 : HeLa treated with 200 ng/mL EGF for 30 minutes
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG (H+L) HRP at 1/10000 dilution
Predicted band size: 92 kDa
Observed band size: 156 kDa why is the actual band size different from the predicted?
Loading control: Beta Actin
IHC image of FGFR1 (phospho Y654) staining in Human breast adenocarcinoma formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab59194, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ICC/IF image of ab59194 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab59194, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
All lanes : Anti-FGFR1 (phospho Y654) antibody (ab59194) at 1/500 dilution
Lane 1 : 293 cell extract treated with insulin (0.01U/ml, 15 mins)
Lane 2 : 293 cell extract treated with insulin (0.01U/ml, 15 mins) with immunizing phosphopeptide
Predicted band size: 92 kDa
Observed band size: 120 kDa why is the actual band size different from the predicted?
Immunofluorescent analysis of COS7 cells labeling FGFR1 (phospho-Tyr654 with ab59194 at 1:100. The image on the right is blocked with the phosphopeptide prior to imunnoflurescent labeling.
This product has been referenced in:
- Murahashi Y et al. Multi-layered PLLA-nanosheets loaded with FGF-2 induce robust bone regeneration with controlled release in critical-sized mouse femoral defects. Acta Biomater 85:172-179 (2019). Read more (PubMed: 30583110) »
- Lee KW et al. FGF11 influences 3T3-L1 preadipocyte differentiation by modulating the expression of PPAR? regulators. FEBS Open Bio 9:769-780 (2019). Read more (PubMed: 30984550) »